The Andersen-Tawil syndrome is rare genetic disorder. It is also known as the Andersen syndrome or long QT syndrome 7. It is a rare genetic disorder characterized by a distinctive pattern of features such as episodes of muscle weakness, differences in facial and body structure, and certain kinds of heart rhythm disturbances. According to the Genetic and Rare Diseases Information Center, approximately 60% of cases of the syndrome are caused by mutations in the KCNJ2 gene.
Report Overview @
Signs and symptoms of Anderson-Tawil syndrome include muscle weakness, developmental abnormalities, and changes in heart rhythm. Physical abnormalities associated with the syndrome include very small lower jaw, low-set ears, unusual curving of the fingers, and an abnormal curvature of the spine. Symptoms generally appear between the ages of 20 and 22 years.
Andersen-Tawil syndrome is diagnosed based on some of identification of characteristic symptoms such as symptomatic arrhythmias, skeletal features, and periodic paralysis. Electrocardiogram or EKG and long exercise nerve conduction studies are also used to diagnose the Andersen-Tawil syndrome.
Increase in the prevalence of Andersen-Tawil syndrome worldwide is anticipated to boost the Andersen-Tawil Syndrome diagnostic and treatment market during the forecast period. A rise in government prioritization of drugs for rare disorders is also likely to boost the market in the near future. However, lack of knowledge about the Andersen-Tawil syndrome is a major restraint of the market. Moreover, a dearth of health care experts in Latin America and Middle East & Africa limits the growth of the Andersen-Tawil Syndrome diagnostic and treatment market in the regions. Nevertheless, increased government funding for diagnosis procedures is likely to offer attractive opportunities for the Andersen-Tawil Syndrome diagnostic and treatment market. Organizations supporting the treatment of this disease globally are Muscular Dystrophy UK, Periodic Paralysis International, Periodic Paralysis Association, and Sudden Arrhythmia Death Syndromes Foundation.
Request Brochure @
The global Andersen-Tawil syndrome diagnostic and treatment market can be segmented based on treatment, diagnostic test, end-user, and region. In terms of treatment, the market can be classified into carbonic anhydrase inhibitors and beta-blockers. Acetazolamide, dichlorpenamide, aldactone and dyrenium are common carbonic anhydrase inhibitors drugs used for the treatment of Andersen-Tawil syndrome. Beta-blockers such as atenolol have been successfully used in some patients as per PubMed research studies.
Based on diagnostic test, the market can be classified into physical test and genetic test.
In terms of end-user, the global Andersen-Tawil Syndrome diagnostic and treatment market can be categorized into hospitals and others. The hospitals segment held a prominent share of the market in 2017.
Based on region, the global Andersen-Tawil syndrome diagnostic and treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for a significant share of the global market in 2017, followed by Europe and Asia Pacific. The U.S. held a major share of the market in North America in terms of revenue. The Andersen-Tawil syndrome diagnostic and treatment market in Asia Pacific is expanding rapidly due to an increase in the number of patients suffering from the disorder in the region. Factor such as better health care infrastructure, economic growth, rise in the number of insurance payers, expanding and developing private health care sector, and increase in awareness among people regarding Andersen-Tawil syndrome diagnostic and treatment are expected to propel the market in the region in the next few years. The Andersen-Tawil Syndrome diagnostic and treatment market in Latin America and Middle East & Africa is projected to expand at a moderate growth rate from 2018 to 2026.